TG Therapeutics, Inc. (NASDAQ:TGTX) has a beta value of 2.22 and has seen 988,952 shares traded in the last trading session. The company, currently valued at $3.82 Billion, closed the last trade at $30.19 per share which meant it gained $0.14 on the day or 0.47% during that session. The TGTX stock price is -5.9% off its 52-week high price of $31.97 and 82.58% above the 52-week low of $5.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.63 Million shares traded. The 3-month trading volume is 1.73 Million shares.

The consensus among analysts is that TG Therapeutics, Inc. (TGTX) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 7 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.41.

TG Therapeutics, Inc. (NASDAQ:TGTX) trade information

Sporting 0.47% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Oct 13 when the TGTX stock price touched $31.97- or saw a rise of 5.57%. Year-to-date, TG Therapeutics, Inc. shares have moved 171.98%, while the 5-day performance has seen it change -2.61%. Over the past 30 days, the shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have changed 21.54%. Short interest in the company has seen 14.01 Million shares shorted with days to cover at 8.1.

Wall Street analysts have a consensus price target for the stock at $44.86, which means that the shares’ value could jump 48.59% from current levels. The projected low price target is $30 while the price target rests at a high of $65. In that case, then, we find that the current price level is +115.3% off the targeted high while a plunge would see the stock lose -0.63% from current levels.

TG Therapeutics, Inc. (TGTX) estimates and forecasts

Figures show that TG Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +134.94% over the past 6 months, with this year growth rate of -4.37%, compared to 8.1% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 40.6% and 2.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be -7.9%.

6 analysts offering their estimates for the company have set an average revenue estimate of $20Million for the current quarter. 6 have an estimated revenue figure of $20Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $38Million and $38Million respectively for this quarter and the next, and analysts expect sales will grow by -47.4% for the current quarter and -47.4% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -3.6% over the past 5 years. Earnings growth for 2020 is a modest +14.9%.